Emerging drugs for the treatment of Waldenström macroglobulinemia.

Abstract excerpt

INTRODUCTION: Waldenström's Macroglobulinemia (WM) is an indolent lymphoma with uniquely distinct and heterogenous clinical and genomic profiles. Clonal lymphoplasmacytic cells secrete monoclonal IgM. More than 90% of patients harbor a mutation in MYD88 gene, leading to the constitutive activation of downstream pathways, involving BTK-mediated signaling. The use of BTK inhibitors has changed the treatment...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Adenine
• Share to Agammaglobulinaemia Tyrosine Kinase
• Share to Drug Design